Identification and characterization of Cardiac Glycosides as senolytic compounds
Triana-Martínez, F.; Picallos-Rabina, P.; Da Silva-Álvarez, S.; Pietrocola, F.; Llanos, S.; Rodilla, V.; Soprano, E.; Pedrosa, P.; Ferreirós, A.; Barradas, M.; Hernández-González, F.; Lalinde, M.; Prats, N.; Bernadó, C.; González, P.; Gómez, M.; Ikonomopoulou, M. P.; Fernández-Marcos, P. J.; García-Caballero, T.; Del Pino, P.; Arribas, J.; Vidal Figueroa, Anxo; González Barcia, Miguel; Serrano, M.; Loza, M. I.; Domínguez, E.; COLLADO RODRIGUEZ, MANUEL
Identifiers
Identifiers
Files view or download
Files view or download
Date issued
2019Journal title
Nature Communications
Type of content
Artigo
Abstract
Compounds with specific cytotoxic activity in senescent cells, or senolytics, support the causal involvement of senescence in aging and offer therapeutic interventions. Here we report the identification of Cardiac Glycosides (CGs) as a family of compounds with senolytic activity. CGs, by targeting the Na+/K+ATPase pump, cause a disbalanced electrochemical gradient within the cell causing depolarization and acidification. Senescent cells present a slightly depolarized plasma membrane and higher concentrations of H+, making them more susceptible to the action of CGs. These vulnerabilities can be exploited for therapeutic purposes as evidenced by the in vivo eradication of tumors xenografted in mice after treatment with the combination of a senogenic and a senolytic drug. The senolytic effect of CGs is also effective in the elimination of senescence-induced lung fibrosis. This experimental approach allows the identification of compounds with senolytic activity that could potentially be used to develop effective treatments against age-related diseases.